B55.2 Mucocutaneous leishmaniasis

Name of the Condition

• Mucocutaneous leishmaniasis

Summary

Mucocutaneous leishmaniasis is a parasitic infection caused by Leishmania protozoa, characterized by lesions that affect both mucous membranes and skin. It is transmitted through the bite of infected sandflies and typically progresses from initial cutaneous lesions to destructive mucosal involvement, particularly of the nose, mouth, or throat. The condition can cause significant disfigurement and functional impairment, depending on the parasite species and host immune response.

Causes

Mucocutaneous leishmaniasis is caused by Leishmania parasites, primarily Leishmania braziliensis and related species. Transmission occurs when infected female sandflies (genus Lutzomyia in the New World) bite humans, introducing parasites into the skin. The parasites multiply within macrophages and may disseminate to mucosal tissues, leading to the characteristic lesions. The disease is endemic in parts of Latin America, where specific sandfly vectors and parasite strains are prevalent.

Risk Factors

• Exposure to sandfly habitats, such as tropical or subtropical regions with high vector activity.
• Immunocompromised states, including HIV/AIDS, chemotherapy, or organ transplantation.
• Residence in or travel to endemic areas, particularly in Central and South America.
• Delayed or inadequate treatment of initial cutaneous lesions, which may allow mucosal spread.

Symptoms

• Persistent or progressive skin ulcers at the site of the sandfly bite.
• Nasal symptoms, including stuffiness, bleeding, or tissue destruction (rhinitis or rhinopharyngitis).
• Oral or pharyngeal lesions, such as painful sores, swelling, or difficulty swallowing.
• Facial disfigurement due to tissue necrosis and scarring over time.
• Secondary bacterial infections in affected mucosal or cutaneous areas.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory testing, and sometimes imaging. Healthcare providers assess lesion characteristics and exposure history. Microscopic examination of tissue samples (e.g., scrapings or biopsies) may reveal Leishmania parasites. Serologic tests or molecular assays (e.g., PCR) can confirm infection, while tissue culture or histopathology may identify the parasite species. Imaging (e.g., endoscopy) may be used to evaluate mucosal involvement.

Treatment Options

Treatment depends on lesion severity, parasite species, and patient factors. First-line therapy often includes systemic antileishmanial medications, such as pentavalent antimonials (e.g., meglumine antimoniate) or amphotericin B formulations. Alternative agents like miltefosine or paromomycin may be used in specific cases. Localized treatments (e.g., topical therapies or intralesional injections) may supplement systemic therapy for cutaneous lesions. Mucosal involvement typically requires prolonged systemic treatment to prevent progression.

Prognosis and Follow-Up

Prognosis varies with early treatment and immune status. With prompt therapy, mucosal lesions may stabilize or improve, though scarring or functional impairment can persist. Delayed treatment increases the risk of severe disfigurement or complications. Follow-up includes monitoring for treatment response, managing secondary infections, and assessing for recurrence. Immunocompromised patients may require extended therapy and closer surveillance.

Complications

• Severe facial disfigurement due to mucosal tissue destruction.
• Chronic pain or difficulty with eating, speaking, or breathing.
• Secondary bacterial or fungal infections in lesions.
• Psychological distress related to appearance or functional limitations.
• Potential for systemic spread in immunocompromised individuals.

Lifestyle & Prevention

• Avoid sandfly bites by using insect repellent, wearing protective clothing, and sleeping under bed nets in endemic areas.
• Promptly treat initial cutaneous lesions to reduce the risk of mucosal spread.
• Maintain good overall health to support immune function, especially in high-risk regions.
• Seek medical care early if symptoms of mucosal involvement develop after a sandfly bite.

When to Seek Professional Help

Consult a healthcare provider if you experience:

• Non-healing skin ulcers following travel to endemic areas.
• Nasal or oral symptoms (e.g., bleeding, pain, or swelling) after a sandfly bite.
• Signs of infection in skin or mucosal lesions, such as increased redness, pus, or fever.
• Worsening of symptoms despite initial treatment or self-care measures.

Tips for Medical Coders

• Code B55.2 is specific to mucocutaneous leishmaniasis and should be used when documentation confirms both mucosal and cutaneous involvement.
• Ensure the diagnosis aligns with clinical findings (e.g., lesion location, exposure history) to support code assignment.
• Differentiate from other leishmaniasis forms (e.g., cutaneous or visceral) based on lesion distribution and organ involvement.
• Verify that the code is not used for asymptomatic or carrier states without active disease.